Favor is hunting for its first-ever chief taco officer. Courtesy of Favor

Do you fancy yourself to be a taco aficionado? If so, you’ll really eat up a new job opening at delivery service Favor.

Owned by San Antonio-based grocery chain H-E-B, Favor is hunting for its first-ever chief taco officer. Yes, a chief taco officer — not to be confused with another type of CTO (chief technology officer).

“The company will pay one energetic, hungry, and social savvy Texan $10,000 to track down the best tacos across the state this summer,” Favor says in a news release.

Aside from the $10,000 in pay, Favor will provide food, accommodations, and transportation in each city, as well as wellness activities such as massages and yoga classes. In addition, the chief taco officer will receive customized Favor swag and one year of free Favor delivery.

“Tacos are one of the top Favored foods across all of the cities we serve throughout Texas,” says Jag Bath, CEO of Favor. “The history and culture behind one of the most iconic foods in the Lone Star State vary from city to city, and we’re excited for our new Chief Taco Officer to discover some of the best and most authentic tacos out there.”

Texas residents over 21 are eligible to apply. Applicants must create and share a short video on why they should be Favor’s chief taco officer, and submit a short form on Favor’s application page. The application deadline is 11:59 pm Thursday, May 12.

Favor’s chief taco officer may want to stock up on digestive aids, given the mass quantity of tacos they’re likely to consume. In 2015, Texas Monthly compiled a list of the 120 Texas tacos “you must eat before you die.” The list highlighted taco purveyors in 15 areas around the state, from Amarillo to Corpus Christi.

By the way, Austin-based outdoor services provider LawnStarter recently crowned Austin the state’s best city for tacos, followed by Round Rock, Dallas, San Antonio, and Houston. But if Favor’s chief taco officer is traversing Texas the entire summer, they’re bound to visit dozens of cities that could argue they deserve the title.

And perhaps Favor’s chief taco officer will do us a favor and crack the shell of Rent.com’s recent ranking of Texas as the No. 2 state for tacos, behind California. Everything’s bigger in Texas, right? That includes our appetite for tacos — and our prowess in producing them.

------

This article originally ran on CultureMap.

Houston was recognized as a growing hub for tech jobs. Photo via VioletaStoimenova/Getty Images

Now hiring: Houston companies are looking to fill thousands of tech positions, according to a new report

by the numbers

Houston isn't stereotypically viewed as a tech hub like Silicon Valley or Austin. Yet the Houston metro area's tech employment base continues to grow at an impressive hub-type pace.

According to CompTIA, a trade group for the IT industry, employers in the Houston area posted openings for 14,714 tech jobs in the third quarter of 2021, up 44 percent from the same period last year. Through the first nine months of this year, Houston-area employers listed nearly 39,000 openings for tech positions.

CompTIA says Microsoft was the most active Houston-area employer last month in terms of postings for tech jobs — 130. It was followed by Deloitte (115) and JPMorgan Chase (52).

Among the most in-demand positions in the Houston area are software developer, software quality assurance analyst, computer user support specialist, computer systems analyst, and database administrator, CompTIA says.

A report released earlier this year by CompTIA ranks Houston as the country's No. 1 metro area for the share of tech workers employed at non-tech businesses — 62.2 percent (compared with 34.8 percent in the Austin metro area). According to the Greater Houston Partnership, this figure helps explain why Houston "isn't a more visible tech hub."

CompTIA tallied 243,908 tech workers in Houston last year, putting it in 11th place for total tech employment among U.S. metro areas. That compares with 426,286 in the San Francisco metro area (No. 4) and 373,695 in Dallas-Fort Worth (No. 11).

The ranks of tech workers in Houston are expanding in part because of an influx of tech talent. Among major metro areas, Houston claimed the No. 2 spot for the next gain of tech workers (10.4 percent compared with the previous 12-month span) moving from other regions from March 2019 to February 2020, according to LinkedIn data cited by the Axios news website. Only Miami ranked higher (15.4 percent).

While Houston may not necessarily be the next Silicon Valley, it "is winning the competition to establish tech hubs in Texas," MarketWatch declared in July.

The article cites the move of the headquarters for Hewlett Packard Enterprise (HPE) from Silicon Valley to Spring as an example of Houston's ascendance in the tech economy. The HPE relocation "offers a vivid snapshot of a new tech frontier," MarketWatch observes, where the energy sector, major local universities, the Texas Medical Center, Mayor Sylvester Turner's office, and the local tech ecosystem are collaborating on cloud computing and other innovations.

"I want the rest of the world to know how much Houston is changing," Amy Chronis, managing director of Deloitte's Houston office, told MarketWatch. "The wakeup call was Amazon looking at candidates for HQ2, and Houston not making the second cut. Not enough technological talent was their reason. It was incorrect, but it lit a fire here."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.